Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of HIV
4.2.2 Increasing Investment in R&D
4.2.3 Increase in Availability of Novel Drugs with Better Efficacy
4.3 Market Restraints
4.3.1 Side Effects of Drugs
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Drug Class
5.1.1 Protease Inhibitors
5.1.2 Integrase Inhibitors
5.1.3 Multi-class Combination Products
5.1.4 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
5.1.5 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
5.1.6 Others
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle-East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle-East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Boehringer Ingelheim International GmbH
6.1.3 Bristol-Myers Squibb Company
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Gilead Sciences, Inc.
6.1.6 Merck & Co, Inc.
6.1.7 Mylan N.V.
6.1.8 ViiV Healthcare


7 MARKET OPPORTUNITIES AND FUTURE TRENDS